DK3288577T3 - Adiponectin-peptidomimetika til behandling af øjenlidelser - Google Patents

Adiponectin-peptidomimetika til behandling af øjenlidelser Download PDF

Info

Publication number: DK3288577T3
Authority: DK; Denmark
Prior art keywords: treatment; eye disorders; adiponectin peptidomimetics; adiponectin; peptidomimetics
Prior art date: 2015-05-01

Application number

DK16789840.2T

Other languages

English (en)

Inventor

Henry Hsu

Original Assignee

Allysta Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-05-01

Filing date

2016-04-29

Publication date

2022-01-10

2016-04-29 Application filed by Allysta Pharmaceuticals Inc filed Critical Allysta Pharmaceuticals Inc

2022-01-10 Application granted granted Critical

2022-01-10 Publication of DK3288577T3 publication Critical patent/DK3288577T3/da

Links

102000011690 Adiponectin Human genes 0.000 title 1
108010076365 Adiponectin Proteins 0.000 title 1
208000030533 eye disease Diseases 0.000 title 1
239000000816 peptidomimetic Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Immunology (AREA)
Toxicology (AREA)
Endocrinology (AREA)
Ophthalmology & Optometry (AREA)
Obesity (AREA)
Child & Adolescent Psychology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Dermatology (AREA)

DK16789840.2T 2015-05-01 2016-04-29 Adiponectin-peptidomimetika til behandling af øjenlidelser DK3288577T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201562156127P	2015-05-01	2015-05-01
PCT/US2016/030142 WO2016179007A1 (en)	2015-05-01	2016-04-29	Adiponectin peptidomimetics for treating ocular disorders

Publications (1)

Publication Number	Publication Date
DK3288577T3 true DK3288577T3 (da)	2022-01-10

Family

ID=57218292

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK16789840.2T DK3288577T3 (da)	2015-05-01	2016-04-29	Adiponectin-peptidomimetika til behandling af øjenlidelser

Country Status (12)

Country	Link
US (6)	US10987401B2 (da)
EP (3)	EP4014985A1 (da)
JP (1)	JP7245649B2 (da)
KR (2)	KR20170141692A (da)
CN (3)	CN107530396B (da)
AU (3)	AU2016257724B2 (da)
CA (3)	CA2981822C (da)
DK (1)	DK3288577T3 (da)
ES (1)	ES2903448T3 (da)
IL (1)	IL272449A (da)
SG (1)	SG11202001140UA (da)
WO (2)	WO2016179007A1 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2903448T3 (es) *	2015-05-01	2022-04-01	Allysta Pharmaceuticals Inc	Peptidomiméticos de adiponectina para el tratamiento de trastornos oculares
WO2018165218A1 (en) *	2017-03-09	2018-09-13	Allysta Pharmaceuticals, Inc	Peptides for dry eye disease
CN107149676A (zh) *	2017-05-05	2017-09-12	杨硕	脂联素和脂联素/胰岛素混合液在改善及治疗眼表角膜上皮及神经损伤中的应用
WO2019061491A1 (en) *	2017-09-30	2019-04-04	Pro Sunfun Biotech Research And Development Co., Ltd.	PEPTIDE FOR OCULAR CARE, COMPOSITION AND METHOD OF USE THEREOF
CN109912685B (zh) *	2017-12-13	2022-05-06	三凡生技研发股份有限公司	眼睛保护胜肽及其组合物及使用该胜肽的用途
US20190292223A1 (en) *	2018-03-23	2019-09-26	Arch Biosurgery, Inc.	Sap and peptidomimetics for treatment of eye disease
CN113164551A (zh) *	2018-10-24	2021-07-23	雅利斯塔制药公司	脂联素肽模拟物制剂
JP7699426B2 (ja) *	2018-11-30	2025-06-27	ロート製薬株式会社	光線による障害からの細胞保護用眼科組成物
BR112022002467A2 (pt)	2019-09-18	2022-07-19	Alcon Inc	Insertos oculares de hidrogel suave embalados a úmido
US11229549B2 (en) *	2019-09-18	2022-01-25	Vance M. Thompson	Tear transplantation and multi-part contact lens with absorbent portion
US11213551B1 (en)	2021-04-05	2022-01-04	Korb Research, Llc.	Ocular treatment compositions and methods of use thereof
WO2023069549A1 (en) *	2021-10-20	2023-04-27	Stealth Biotherapeutics Inc.	Methods and compositions comprising peptidomimitics for treating, preventing, inhibiting, ameliorating or delaying the onset of ophthalmic conditions
WO2023069255A1 (en) *	2021-10-20	2023-04-27	Stealth Biotherapeutics Inc.	Methods and compositions comprising peptidomimitics for treating, preventing, inhibiting, ameliorating or delaying the onset of ophthalmic conditions
WO2023107796A1 (en) *	2021-12-11	2023-06-15	The Regents Of The University Of California	Ophthalmic formulations for macular degeneration
WO2024180472A1 (en)	2023-02-28	2024-09-06	Alcon Inc.	Ocular inserts
KR102609115B1 (ko) *	2023-06-08	2023-12-05	주식회사 엔큐라젠	펩타이드를 포함하는 안구 질환의 치료용 조성물
WO2026032238A1 (en) *	2024-08-06	2026-02-12	The Chinese University Of Hong Kong	Compositions and methods for treating tendon and ligament injuries utilizing biomaterials and adiponectin or its mimics
WO2026049532A1 (ko) *	2024-08-30	2026-03-05	서울과학기술대학교 산학협력단	알레르기성 결막염 치료를 위한 약학적 제제가 담지된 콘택트렌즈 및 이의 제작 방법

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5108921A (en)	1989-04-03	1992-04-28	Purdue Research Foundation	Method for enhanced transmembrane transport of exogenous molecules
US5643575A (en)	1993-10-27	1997-07-01	Enzon, Inc.	Non-antigenic branched polymer conjugates
US5824784A (en)	1994-10-12	1998-10-20	Amgen Inc.	N-terminally chemically modified protein compositions and methods
DE4437604A1 (de)	1994-10-21	1996-04-25	Basf Ag	Konjugate aus einem Poly- oder Oligopeptid und einer niedermolekularen lipophilen Verbindung
US5932462A (en)	1995-01-10	1999-08-03	Shearwater Polymers, Inc.	Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
DE69936409T2 (de)	1998-04-28	2008-04-17	Laboratoires Serono S.A., Coinsins	Verfahren zur schrittweise Bindung von Polyethylenglykol (PEG) an Polypeptide
GB9814527D0 (en)	1998-07-03	1998-09-02	Cyclacel Ltd	Delivery system
JP2005535561A (ja) *	2002-01-18	2005-11-24	プロテミックスコーポレイションリミティド	アディポネクチンのグリコアイソフォームとその使用
AU2006242651B2 (en) *	2005-04-29	2013-05-16	The Regents Of The University Of California	Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
WO2012142142A2 (en)	2011-04-12	2012-10-18	Temple University - Of The Commonwealth System Higher Education	Adiponectin receptor agonists and methods of use
KR101438744B1 (ko) *	2012-08-02	2014-09-15	전남대학교산학협력단	아디포넥틴을 유효성분으로 포함하는 안구건조증 또는 염증성 안구표면 질환의 예방 또는 치료용 조성물
WO2014066775A1 (en) *	2012-10-26	2014-05-01	Forsight Vision5, Inc.	Ophthalmic system for sustained release of drug to eye
ES2903448T3 (es) *	2015-05-01	2022-04-01	Allysta Pharmaceuticals Inc	Peptidomiméticos de adiponectina para el tratamiento de trastornos oculares

2016
- 2016-04-29 ES ES16789840T patent/ES2903448T3/es active Active
- 2016-04-29 DK DK16789840.2T patent/DK3288577T3/da active
- 2016-04-29 JP JP2018508628A patent/JP7245649B2/ja active Active
- 2016-04-29 EP EP21204663.5A patent/EP4014985A1/en not_active Withdrawn
- 2016-04-29 AU AU2016257724A patent/AU2016257724B2/en active Active
- 2016-04-29 CN CN201680023972.XA patent/CN107530396B/zh active Active
- 2016-04-29 US US15/571,039 patent/US10987401B2/en active Active
- 2016-04-29 EP EP16789840.2A patent/EP3288577B1/en active Active
- 2016-04-29 WO PCT/US2016/030142 patent/WO2016179007A1/en not_active Ceased
- 2016-04-29 CA CA2981822A patent/CA2981822C/en active Active
- 2016-04-29 KR KR1020177031104A patent/KR20170141692A/ko not_active Ceased
- 2016-04-29 CN CN202210970186.8A patent/CN115919996A/zh active Pending
- 2016-04-29 CA CA3191203A patent/CA3191203A1/en active Pending
2017
- 2017-08-14 US US15/676,968 patent/US10537608B2/en active Active
2018
- 2018-08-07 WO PCT/US2018/045527 patent/WO2019036223A1/en not_active Ceased
- 2018-08-07 CN CN201880052451.6A patent/CN111032070A/zh active Pending
- 2018-08-07 KR KR1020207007015A patent/KR20200039749A/ko not_active Ceased
- 2018-08-07 EP EP18845611.5A patent/EP3668530A4/en not_active Withdrawn
- 2018-08-07 SG SG11202001140UA patent/SG11202001140UA/en unknown
- 2018-08-07 AU AU2018318008A patent/AU2018318008A1/en not_active Abandoned
- 2018-08-07 CA CA3071670A patent/CA3071670A1/en active Pending
2019
- 2019-11-24 US US16/693,355 patent/US11273197B2/en active Active
2020
- 2020-02-04 IL IL272449A patent/IL272449A/en unknown
2021
- 2021-01-11 US US17/146,397 patent/US11464825B2/en active Active
- 2021-05-20 AU AU2021203254A patent/AU2021203254A1/en not_active Abandoned
2022
- 2022-02-24 US US17/680,181 patent/US20220331393A1/en not_active Abandoned
- 2022-10-04 US US17/937,849 patent/US20230074446A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20180078616A1 (en)	2018-03-22
HK1246178A1 (zh)	2018-09-07
JP2018514592A (ja)	2018-06-07
IL272449A (en)	2020-03-31
US10987401B2 (en)	2021-04-27
AU2021203254A1 (en)	2021-06-17
US11273197B2 (en)	2022-03-15
EP4014985A1 (en)	2022-06-22
US20200085907A1 (en)	2020-03-19
CA2981822A1 (en)	2016-11-10
EP3288577B1 (en)	2021-10-27
JP7245649B2 (ja)	2023-03-24
AU2016257724A1 (en)	2017-10-12
CN111032070A (zh)	2020-04-17
KR20200039749A (ko)	2020-04-16
EP3288577A1 (en)	2018-03-07
US11464825B2 (en)	2022-10-11
EP3668530A1 (en)	2020-06-24
KR20170141692A (ko)	2017-12-26
SG11202001140UA (en)	2020-03-30
WO2016179007A1 (en)	2016-11-10
ES2903448T3 (es)	2022-04-01
CA3191203A1 (en)	2016-11-10
US20180161390A1 (en)	2018-06-14
US20210128671A1 (en)	2021-05-06
CN115919996A (zh)	2023-04-07
EP3288577A4 (en)	2018-12-26
US20220331393A1 (en)	2022-10-20
WO2019036223A1 (en)	2019-02-21
US20230074446A1 (en)	2023-03-09
EP3668530A4 (en)	2021-07-21
AU2016257724B2 (en)	2021-02-25
CA3071670A1 (en)	2019-02-21
AU2018318008A1 (en)	2020-02-06
CN107530396B (zh)	2022-08-26
CN107530396A (zh)	2018-01-02
CA2981822C (en)	2023-04-11
US10537608B2 (en)	2020-01-21

Publication	Publication Date	Title
IL285151A (en)	2021-08-31	Methods of treating fgf21-associated disorders
DK3570844T3 (da)	2023-11-13	Azolopyrimidin til behandlingen af kræftrelaterede lidelser
IL272449A (en)	2020-03-31	Adiponectin peptide deletions for the treatment of ocular disorders
DK3501542T3 (da)	2026-04-20	Esketamin til behandling af depression
DK3261640T3 (da)	2022-07-11	5ht-agonister til behandling af epilepsilidelser
DK3185876T3 (da)	2022-10-31	Sammensætninger og fremgangsmåder til behandling af neurologiske lidelser
DK3125875T3 (da)	2023-07-24	Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande
DK3433266T3 (da)	2025-08-25	Fremgangsmåder til behandling af mitokondrieforstyrrelser
DK3286311T3 (da)	2021-05-17	Fremgangsmåde til behandling af maligniteter
DK3119397T3 (da)	2022-03-28	Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser
DK3466432T3 (da)	2020-09-28	Fremgangsmåder til behandling af pulmonale non-tuberkuløse mykobakterielle infektioner
DK3325443T3 (da)	2022-07-18	Fremgangsmåde til fremstilling af pridopidin
DK3240612T3 (da)	2021-01-18	Fremgangsmåder til behandling af nethindesygdomme
DK3503890T3 (da)	2025-01-27	Anvendelse af pridopidin til behandling af dystonier
DK3362066T3 (da)	2021-11-22	Kombinationsterapi til behandling af maligniteter
DK3524255T3 (da)	2020-11-09	Sammensætning til behandling af acne
EP3286605A4 (en)	2019-01-09	LIGHT-SENSITIVE POLYIMIDE COMPOSITIONS
DK3481846T3 (da)	2021-08-16	11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande
DK3390390T3 (da)	2021-12-06	Bipyrazolylderivater egnede til behandling af autoimmunsygdomme
DK3324824T3 (da)	2024-12-02	Fremgangsmåde til behandling af binokulare dysfunktioner
DK3157534T3 (da)	2022-08-22	Acetylcholinesterasehæmmere til behandling af dermatologiske tilstande
DK3579826T3 (da)	2026-03-09	Fremgangsmåder til behandling af cdkl5-lidelser med forbindelsen ov329
DK3430143T3 (da)	2021-03-29	Inhibitorer af SRSF1 til behandlingen af neurodegenerative sygdomme
DK3439661T3 (da)	2021-10-18	Fremgangsmåder til behandling af øjenlidelser
DK3307267T3 (da)	2019-07-01	Behandling af multipel sklerose